Yüksel Ürün/X
May 20, 2025, 10:19
Yüksel Ürün: KEYNOTE-991 Trial Results in mHSPC Treatment
Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared an article on X:
“KEYNOTE-991: Pembrolizumab plus Enzalutamide and ADT vs Placebo plus Enzalutamide and ADT in treatment-naive mHSPC.
- Did not improve rPFS.
- No OS benefit.
- More toxicity.”
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study.
Authors: C. Gratzke, M. Özgüroğlu, A. Peer, M.A.N. Sendur, M. Retz, J.C. Goh, W. Loidl, G. Jayram, S.-S. Byun, C. Kwak, M. Kwiatkowski, R.M. Kopp, J.C.V. Limón, J.F.E. Penagos, U. De Giorgi, K.M. da Trindade, C. Niu, Y. Liu, C.H. Poehlein, and J.M. Piulats.
You can read the full article on Journal of ESMO Annals of Oncology.
More posts featuring Yüksel Ürün.
A. Peer
ADT
androgen deprivation therapy
C. Gratzke
C. Kwak
C. Niu
C.H. Poehlein
cancer
Enzalutamide
ESMO Annals of Oncology
fight against cancer
G. Jayram
Global fight against cancer
J.C. Goh
J.C.V. Limón
J.F.E. Penagos
J.M. Piulats.
K.M. da Trindade
KEYNOTE-991 Trial
M. Kwiatkowski
M. Özgüroğlu
M. Retz
M.A.N. Sendur
Metastatic Hormone-sensitive Prostate Cancer
mHSPC treatment
OncoDaily
Oncology
pembrolizumab
placebo
R.M. Kopp
rPFS
S.-S. Byun
U. De Giorgi
W. Loidl
Y Liu
Yüksel Ürün
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 20, 2025, 17:22
May 20, 2025, 16:37
May 20, 2025, 16:27
May 20, 2025, 15:05